Biophytis Announces 2022 Financial Results and 2023 Perspectives
Retrieved on:
Tuesday, April 18, 2023
EUA, Amount of substance, EAP, Euronext Growth, Duchenne muscular dystrophy, SARA, CMA, Therapy, CET, Marketing, Bank statement, AMD, COVID-19, Clinical trial, Ageing, Research, MACA, Trial of the century, EMA, FAMHP, Death, Spinal muscular atrophy, Investigational New Drug, DMD, Patient, Risk, AMF, 237th Rifle Division, FDA, Phase, IND, Respiratory failure, Safety, Cryptocurrency, Pharmaceutical industry, Dietary supplement, SMA, Sarcopenia
€11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024
Key Points:
- €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024
Paris, France, Cambridge (Massachusetts, United States), April 18th, 2022 – 8am CET - Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023. - Stanislas Veillet, President and CEO of Biophytis, stated: “In a difficult economic and financial environment, 2022 was a crucial year for Biophytis.
- Scientific communication in international congresses of the main results of the SARA (Sarcopenia) and MYODA (Duchenne Muscular Dystrophy) programs.
- The Company’s annual 2022 non-audited consolidated financial statements prepared in accordance with IFRS were reviewed by the Company’s Board of Directors on April 14, 2023.